SLXP | Quote | Chart | News | PowerRating -- Salix Pharmaceuticals reported stronger third-quarter sales of its drugs to treat various gastrointestinal diseases.
The Morrisville company announced Monday that revenue rose to $65.7 million, up 53 percent from the same period last year. Salix reported a net loss of $7.3 million, or 15cents a share. But the results beat the average expectation of Wall Street analysts.
Salix shares have more than tripled since March as investors grew optimistic aboutSalix. The stock closed at $21.14 Monday, up 20 cents.
Salix, one of the Triangle's most successful drug companies, has several products on the market and promising treatments in development. Salix recently hired 64 salespeople to help market its medicines to physicians.
"The third quarter of 2009 was one of the most exciting and rewarding periods in the company's history to date," CEO Carolyn Logan said.
To see more of The News & Observer, or to subscribe to the newspaper, go to
http://www.newsobserver.com. Copyright (c) 2009, The News and Observer, Raleigh,
N.C. Distributed by McClatchy-Tribune Information Services. For reprints, email
tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax
to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave.,
Suite 303, Glenview, IL 60025, USA.
For full details on Salix Pharmaceuticals Ltd (SLXP) SLXP. Salix Pharmaceuticals Ltd (SLXP) has Short Term PowerRatings at TradingMarkets. Details on Salix Pharmaceuticals Ltd (SLXP) Short Term PowerRatings is available at This Link.
- Salix Pharmaceuticals Releases 4th Quarter and 2009 Financial Results - 03/15/10
- Salix Pharmaceuticals Posts 4Q and FY 2009 Results - 03/11/10
- Salix Pharmaceuticals Ltd (SLXP) Corporate Event Announcement Notice - 03/10/10
- Salix expects big drop in sales - 03/10/10
- BiomedReports: News and FDA Updates for Salix (NASDAQ:SLXP), Teva (NASDAQ:TEVA), Urigen (OTC:URGP) - 03/10/10
- More News >>


